Cost-Effectiveness Analysis of rFVIIIFc Versus Contemporary rFVIII Treatments for Patients with Severe Hemophilia A Without Inhibitors in the United States

BACKGROUND: A range of treatments for patients with severe hemophilia A (HA) have been developed over the last decade, allowing for reduced frequency of administration and improved outcomes (joint health and breakthrough bleeding rates). While clinically effective, the cost effectiveness of these tr...

Descripción completa

Detalles Bibliográficos
Autores principales: Bullement, Ash, Knowles, Emma S., DasMahapatra, Pronabesh, Ali, Talaha, Preblick, Ron
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer International Publishing 2021
Materias:
Original Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8611150/
https://www.ncbi.nlm.nih.gov/pubmed/34268704
http://dx.doi.org/10.1007/s41669-021-00283-6

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8611150/
https://www.ncbi.nlm.nih.gov/pubmed/34268704
http://dx.doi.org/10.1007/s41669-021-00283-6

Ejemplares similares